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The active opioid-enhancing substance(s) in amniotic fluid and placenta. rel"crred tIl as POEF (placentnl opioid-enhancing fac lor). does not produce antinociception by itself. Evidence sug gests thnl POEF mav exclusively enhance opioid-medialCd anti nociccption: the ingestion of amniolie fluid does nol enhance the nonopioid-ll1ediated nntinoeiceplion produccd by aspirin (15) . Thc cnhancement by POEF of antinociceplion produced by other nonopioid mechanisms has yet to be fully exmllined.
Nicotinc injection has been shown to produce antinocicep tion in a variety of species (12.20) . including. mice and rats (2~7, 9-11.20-22.24-26) . Evidence suggests a primarily central site of action. been use nicot ine administered subcutaneouslv (SC) or intri:lcerebroventricularly (ICY) produced anlinociception thm was blocked by pretreatmcnt with Sc. intraperitoneal. or ICY ndministration of mecamylamine. a tertiary nicotilic re ceptor antagonist that readily crosses the blood·-br~lin barrier (5.11.22.24-26) . Peripherally injected chlorisondamine. it bisqua ternary peripheral antagonist specific for nicot inc, completely failed 10 block niCOline-induced antinocieeptioll in the hot plate assay (5) , the assay used in the present set of experiRcqucsts 1"01' rc'prinls should be ,Iddrcsscd to Mark B. Krista!. Department of Psychology. IJnivcrsitv at BufLtlo. 13uff,t1o. :--.iY 1.:I26n. E-nwil: kri,t;lll.dacsu.hll I'Ll 10.cdu ments. It should be noted, however, that peripherally injected chlorisondamine did successfully block nicotine antinocicep tion when tested in a hot-water tail-dip assay, suggesting the possible presence of a peripheral component to nicotine's ef fects on the tail withdrawal response (5) . A central site of ac tion is further indicated by studies showing that nicotine induced antinociception is greatest after injection into the pe dunculopontine tegmental nucleus of the mesopontine teg mentum, areas of the ventral and posterior medulla, the cen tral gray, or the subarachnoid space (2, [9] [10] [11] 24) .
Nicotine-induced antinociception in the rat Inay be medi ated by several neurotransmitter systems, including adrenergic, serotonergic, and cholinergic muscarinic systems (10, 24, 26) . Al though endogenous opioid systems may be involved in nico tine-induced antinociception in mice (3, 26) and dogs (12) , there is little evidence to suggest opioid involvement in rats. Rats pretreated with the opiate antagonist naloxone SC still exhib ited antinociception after either SC or suhcortical nicotine in jection (11, (24) (25) (26) . However. Davenport, Houdi, and Van Loon (7) found that ICV nicotine pretreatnlent significantly increased morphine-induced antinociception in rats treated with [3-funaltrexamine, an irreversible J-L-opioid receptor an tagonist. They contended that nicotine caused the release of endogenous opioids. which then occupied J-L-opioid receptor sites and prevented [3-funaltrexamine from inactivating those receptor sites. In the present study. all rats were pretreated with the opiate antagonist naltrexone to ensure that any possi hIe endogenous opioid release would not affect antinocicep tion. The presence of nicotine-induced antinociception in these rats would lend support to the findings of others that endoge nous opioids are not involved in nicotine-induced antinocicep tion in the rat. The present experiments were conducted to de termine whether the ingestion of amniotic fluid by rats enhances the antinociceptiol1 produced hy nicotine injection.
EXPERIMENT I A Previous testing of POEF enhancenlent of opioid-medi ated antinociception has primarily been conducted using the tail-flick latency test. We decided to use a hot-plate assay in the present experiment because it is frequently used to assess antinociception produced by nicotine (5, (9) (10) (11) 20, 22, 24) . There fore, it was important to demonstrate the presence of POEF enhancement of opiate-mediated antinociception using the hot-plate assay before testing for POEF enhancement of nico tine-induced antinociception.
Methods
Subjects. All live animal experimental procedures were ap proved by IACUC, SUNY at Buffalo, Buffalo, New York. Fe male Long-Evans rats (n = 40) weighing 266.45 ± 2.91 g were used as suhjects. All rats were housed in hanging wire-nlesh cages (24.5 X 18 X 18 cm) in an environmentally controlled roonl maintained on a 14 L: 10 0 cycle. Rats had ad lib access to water and chow (Agway Prolab Rat/Mouse/Hamster For mula 3000), except as noted. Prior to testing, daily vaginal smears were obtained to check for norn1al estrous cyclicity in each rat. Vaginal smears were also taken on the day of testing to assign rats to groups in such a way that would ensure that the groups contained approximately equal numbers of rats in each stage of the estrous cycle. Testing was conducted be tween 5 and 7 h after lights-on.
Apparatus. Pain threshold was assessed hy means of a hot plate algesiOlneter (lITC Inc./Life Science Instruments model 390) nlaintained at 52t:t~ (5,10.11). Antinociception was mea-ROBINSON-VANDERWERF ET AL.
sured by placing each rat on the center of the hot plate so that all four paws touched the plate simultaneously. As all four paws contacted the surface, a stopwatch was started to mea sure the latency from paw contact until the rat either licked its hindpaw or jumped. If the rat failed to perform the required behavioral end point within 55 s, testing was terminated.
Procedure. A 2 X 2 design was used: drug (morphine sul fate 4.0 mg/kg, vehicle 1 ml/kg) X enhancer [0.25 ml amniotic fluid (AF). 0.25 ml saline (SAL)], n = 10/group. Prior to test ing, subjects were habituated to all testing procedures. Sub jects were exposed to a room-temperature plate for 5 min on each of the two days before the day of testing. Each rat was also given one blank orogastric infusion (no fluid was admin istered) each day for five consecutive days.
On the day of testing, suhject rats were food-and water deprived for a 3-h period. Each rat was then injected with 0.9% saline (l ml/kg SC) to control for the naltrexone injec tion given to subjects in experiments 1Band 2. After 25 min, each rat was injected (SC) with morphine sulfate (4.0 mg/kg) or vehicle (1.0 ml/kg saline). Thirty minutes after morphine injection, subjects were given an orogastric infusion of en hancer (0.25 Inl AF) or control (0.25 ml SAL). Antinocicep tion was measured on the hot plate 15 min later.
Results
A two-way ANOVA showed a significant main effect of nlultiple-range test (a level = p < 0.05) showed that rats given morphine + AF showed a significantly higher level of antinoci ception than did rats given nl0rphine + SAL, vehicle + AF. or vehicle + SAL (see Fig. 1 ). Rats that received morphine + AF showed a mean latency to lick their hindpaw or jun1p of 27.20 ± 4.13 s, whereas rats given morphine + SAL showed a mean latency of 17.56 ± 2.11 s. Rats given vehicle + AF showed a mean latency of 10.45 ± 1.27 s, and rats receiving vehicle + SAL showed a n1ean latency of 11.67 ± 1.33 s.
Therefore, AF (and presumably POEF) enhanced the anti nociception produced by a low dose of morphine (4.0 mg/kg). 
Morphine Vehicle
FlG. 1. Mean (~SEM) hindpaw lick/jump latency of rats treated with 4.0 mg/kg morphine (SC) or 1 mg/kg vehicle followed by orogastric infusion of 0.25 ml amniotic fluid or 0.25 ml saline: 11 IOJ group. Latency was significantly greater for the morphine/AF combination than for the others (morphine/Sal = vehicle/AF --' vehicle/Sal), jJ < 0.05.
FXPERJMENT JB

Methods
Suhjecls. Female Long-Evans rats (n ::: 104) weighing 261 ::' :: 1.82 g were housed and maintained as described for experi ment lA.
Drugs. Nicotine bitartmte (Sigma Chemical Co., St. Louis, MO, USA) W<l~ diluted to final concentrations of 0.075 mg/ml, 0.125 mg/ml, and 0.225 mglml (free base) in a 0.9% saline so lution. Drugs were administered SC at a volume of 1 nJJJkg.
Doses of nicotine higher than 0.225 mg/kg were not used be cause rats given doses higher than that in pilot tests failed to perform the required behavioral end point within 55 s (Le., the higher doses produced a ceiling effect). Naltrexolle HC] for which n = 1.0. hior to testing, all subjects were habituated to all testing procedures as described in experirncllt IA.
On the day of testing, rats were deprived of food <:lIlU water for 3 h. Each rat was then pretreated with the opiate blocker naltrexone (1 mg/kg SC) (15) . Sixty minutes later. each re ceived an orogastric infusiOD of enhancer (0.25 ml AF) or con trol (0.25 ml SAL). Ten minutes after the infusion, <:ach rat was injected SC with nicotine (0.075 mg/kg. 0.125 mglkg, or 0.225 mg/kg) or vehicle (J mlikg). AntinociceptioD W(lS mea sured on thc hot plate 10 min after the nicotine injection: pilot dala [TOm our laboratory indicatcd that nicotine-induced anti nociception is at its peak at lhi~ time.
Resulrs
There were no significant differences among the three co hort groups of rats receiving vehicle injection + SAL infusion, therefore the groups were combined for purposes of analysis (u level = p < 0.05). There were also nO significant difkrtllce~ among the three cohort groups receiving vehicle injection + AF inJusion; thl:se thrte:: groups also were:: combined. This re duced the design of the experiment lo 4 X 2: dose (0.0 mg/kg. 0.075 mg/kg, 0.125 mg/kg. 0.225 mg/kg) x enhancer (0.25 1)11 AF, 0.25 ml SAL). A two-way ANOVA revealed a significant m~in effect of dose [F(3. 96) = 13.62. P < 0.0001)' There was no significant main effect of enhancer nor was there a dose x enhancer interaction. Therefore, amniotic fluid did nor en hance the antinociception produced by variou~ dosc:s of nico tine (see Fig. 2 truncated because, as mentioned above. doses of nicotine higher than 0.225 mglkg could not be administered to our rats without producing a ceiling effect in the hot-plate assay.
1t is possible that enhancement of nicotine-induced anti noci.:;eptiol1 by amniotic fluid was not apparent becausc the amount of POEF contained in the volume o( the ilmuiotic fluid infusion used was not appropriate to enhance antinocicep tion in this situation. A dose of 0.25 ml amniotic fluid was cho sen for experiment lil because previous data from our labora tory have shown that 0.25 ml oC amniotic fluid significllnlly enhances the anrinociceptiofl produced by a lIJIeshold dose (3.0 mg/kg) of morphine (14, 16) . We illlempted to address the issue of amniotic fluid volume in experiment 2 by injecting ra ts with a single, effective dose of nicotine (or veh icl e) and infusing them with v,uiolls volumes of amniotic tluid or saline. A dose of 0.12S mg/kg nicotine wa~ chosen for this experi ment because it produces a significant level of antinociception without producing a ceilmg effect (55 s maximum) in our test ing paradigm (ste fig. 2 ). Therefore. the dose is appropriate for manipulations likdy to result in enhancement. That dose of nicotine abo produl:es a lcvd of antinociception roughly equivalent to thal produced by 4,0 mg/kg morphine, the dose that produced enhanceahle antinociception in experiment lA.
EXPERtY1E'iT 2
J'vfelhods
Subjects. Female Long-Evans rals (n ::: 132) weighing 270 :::
2.14 g wcrl: housed and maintained as described in exp~rj mentlA. Procedure. A 2 X 2 x 3 design was used; dl1lg (nicotine 0.125 mg/kg, vehicle I ml/kg) x enbanctr (M. SAL) x en hanccr volume (0.125 m!. 0.25 mi. 0.5 ml), with no repeated measure~. Each ccll contained 11 = 10, except the four groups receiving 0.5 Illi amniotic fluid, for which I/. = 13. Prior to test ing, subjects were habituated \0 all testing procedures as de scribed in experiment lA. On the day of testing, each subject rat was deprived of food and water for 3 h. Each rat was pretreated with naltrex one Hel (1 ml/kg SC). Sixty minutes later, each received an orogastric infusion of AF or SAL (0.125 ml, 0.25 ml, or 0.5 ml). Ten minutes after the infusion, each rat was given an injection of either nicotine (0.125 mg/kg SC) or vehicle (1 n11/kg SC). Antinociception was measured on the hot plate 10 min after the nicotine injection.
ReSlllts
There were no significant differences (ex level = p < 0.05) among control groups of rats receiving nicotine-vehicle injec tion and the three volumes of saline infused as a control for amniotic fluid (0.125, 0.25, or 0.5 ml saline); therefore, these groups were combined for purposes of analysis. Likewise, there were no significant differences among rats receiving nic otine injection and any of the three infused volulnes of saline; therefore, these groups were also cOlnbined for purposes of analysis. A two-way ANOV A revealed only a significant ef fect of drug [nicotine> vehicle: F( 1,120) = 31.3Lp < 0.0001] (sec Fig. 3 ). Rats receiving nicotine showed a mean latency to lick or jump of 21.60 ± 1.78 s; those receiving nicotine vehicle showed a mean latency of 10.89 ± 0.62 s. There was no signif icant main effect of enhancer volume, nor was there a drug X enhancer volume interaction. Although it may appear in Fig.   3 that rats receiving nicotine + 0.25 ml AF (28.46 ± 5.97 s)
showed a somewhat greater level of antinociception than did rats receiving nicotine + 0.0 ml AF (20.00 ± 2.39 s), which would indicate enhancement by amniotic fluid, this was not the case. There was no statistically significant difference be- Varying the volume of amniotic fluid infusion had no signifi cant effect on nicotine-mediated antinociception.
GENERAL DISCUSSION
The presence of nicotine-induced antinociception in rats pretreated with naltrexone in this study is consistent with the findings of others that antinociception produced by nicotine is not mediated by opioid mechanisms in the rat (1 L24~26). Nic otine may indeed cause a release of endogenous opioid, as suggested by Davenport et al. (7), but that release. in rats, ap parently does not mediate the antinociception produced by nicotine. In the present study, pretreatInent with naltrexone, a general opiate antagonist, should have prevented any endoge nous opioid release from producing antinociception.
Nicotine administered SC produced antinociception that was not enhanced by amniotic fluid ingestion. V (Hying the dose of nicotine or the volume of amniotic fluid did not pro duce enhancement of nicotine-induced antinociception. It should be noted that although optimum levels of various pa rameters (hot-plate temperature, dose of naltrexone, interval between injection and test, etc.) were used (as determined by pilot studies, previous research in our laboratory, or refer ences in the literature) and provided support for our hypothe sis, these results might not apply to all other combinations of parameters. Nevertheless, amniotic fluid ingestion did en hance the antinociception produced by a low dose of mor phine. POEF enhancement of morphine-induced antinocicep tion in the present hot-plate study agrees with recent work, using a hot plate, that showed that selective activation of the 80pioid receptor with ICV-administered DPDPE produced antinociception that was enhanced by ingcstion of placenta (8) . Although there is the possibility that the abscnce of en hancement by amniotic fluid of nicotine-induced antinocicep tion resulted from the assay choscn, this possibility is largely eliminated by the demonstration that the hot-plate assay is sensitive to POEF enhancement of opiate-mediated antinoci ception. Our results are consistent with earlier work showing that amniotic fluid ingestion did not enhance the nonopioid mediated antinociception produced by aspirin ( 15) , and furt her support our contention that the enhancement of antinociccp tion by POEF is specific to opioid-mediated antinociception. These findings also support growing evidence that the benefit of ingestion of amniotic fluid and placenta by parturient mam mals is the enhancement of opioid-mediated antinociception that occurs from late pregnancy through parturition ( 13) .
